Article citationsMore>>

Zhang, X.X., Wang, R.D., Ding, Y.H., et al. (2024) Safety and Efficacy of DEB-TACE in Combination with Lenvatinib and Camrelizumab for the Treatment of Unresectable Hepatocellular Carcinoma (uHCC): A Two-Centre Retrospective Study. Frontiers in Immunology, 15, Article 1422784.
https://doi.org/10.3389/fimmu.2024.1422784

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top